DIRS.INFO The most relevant business & tech news

☆ 2 takeaways from our daily meeting: Stocks await Fed decision, Club earnings recap
▼ + stars: | 2022-11-02 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Fed decision ahead Quick takes on Club earnings 1. Fed decision ahead Stocks edged down Wednesday ahead of the Federal Reserve's decision on interest rate increases, set for this afternoon. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ What Cramer is watching Wednesday — Fed day, AMD signs of life, China hits Estee Lauder
▼ + stars: | 2022-11-02 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

While missing lowered expectations in the third quarter, Club holding AMD did see a year-over-year revenue growth. Club holding Estee Lauder (EL) beats on fiscal first-quarter earnings and matches on revenue. Club holding Devon Energy (DVN): Very strong quarter . Club holding Humana (HUM) sees membership growth. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Organizations: & $

☆ Eli Lilly's guidance cut is about the strong dollar, not weakening fundamentals, CEO says
▼ + stars: | 2022-11-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Eli Lilly — which generates about 40% of its sales overseas — largely attributed the guidance cut to the strong U.S. dollar. With three quarters already reported, Eli Lilly now expects full-year sales to range between $28.5 billion to $29 billion and adjusted per-share earnings between $7.70 to $7.85. New diabetes drug off to great start One of our biggest reasons for liking Eli Lilly is the company's new type 2 diabetes drug that's also shown promise as an obesity treatment . The drug is similar to one that Eli Lilly is working to treat the most common form of dementia. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC

☆ A top Wall Street analyst lays out how two blockbuster drugs are poised to turn Eli Lilly into the best Big Pharma stock and says now is the time to buy
▼ + stars: | 2022-09-22 | by ( Sarah Braner | ) www.businessinsider.com time to read: +2 min

Analysts at UBS said Eli Lilly is their top Big Pharma stock pick. They said Lilly's obesity and diabetes drug Mounjaro will likely top Wall Street's sales estimates. The experimental Alzheimer's drug lecanemab could help boost the stock too. Lilly's stock gained 3.2% to $305.80 on Thursday morning. They also touted the potential of Lilly's experimental Alzheimer's drug donanemab, saying it has a 60% chance of success.

☆ Analyst loves Eli Lilly for its potential blockbuster obesity drug — and we do, too
▼ + stars: | 2022-09-22 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Club holding Eli Lilly 's (LLY) new diabetes treatment might become "the biggest drug ever" if it were to also get regulatory approval as an obesity drug, UBS wrote in a note to clients Thursday. Eli Lilly shares jumped more than 3% in Thursday's session. Bottom line We also think Eli Lilly is a buy here. As noted, Eli Lilly has a long history developing and selling diabetes drugs. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

Search resuls for: "Ricks"

5 mentions found